Share:
Despite some recent angst about whether there will be a sufficient supply of cannabis to meet the needs of registered medical patients as Canada rolls out its nationwide adult-use program, there is reason for keeping confident about the future of its medical cannabis market . As detailed in New Frontier Data’s latest report, The Canada Cannabis Report: 2018 Industry Outlook there remains an immense amount of growth still to come in the Canadian medical market, especially as insurance programs continue to adopt cannabis in company benefits programs. Even after the rollout of Canada’s pending nationwide adult-use market, “there will remain a strong need for cannabis clinics for years to come,” said Paul Methot, president of Knalysis Technologies. “Some licensed producers will focus on the rec market, but those with the best medicine will keep their loyal patients coming, and the margins on medical cannabis is predicted to remain higher than [adult-use] strains.”
Methot cites how medical patient participation in Canada grew 539 percent between December 2015 and December 2017 (from 53,649 patients to 269,502), fueling the need for the specific solutions. Knalysis Technologies is part of the Canada House Wellness Group, a publicly traded Canadian company with one of the largest networks of cannabis clinics in Canada. Knalysis pioneered software to seamlessly link physicians, providers, and patients. Its client base currently represents 6 percent of Canada’s registered patients nationwide. Some particular points made from Knalysis’ data include:
Twenty percent of males (versus 8 percent of women) consume more than 5 grams of cannabis daily. Male veterans consume at significantly higher rates than any other group – 27 percent consume more than 5 grams per day. The large veterans population in Knalysis’ database makes PTSD the most commonly cited condition for which cannabis is prescribed: 20 percent of men and 8 percent of women report using cannabis for PTSD, compared to 5 percent of men and 6 percent of women who use it for chronic pain. Women were a little more likely to use cannabis for anxiety, depression and fibromyalgia, whereas men were more likely to consume cannabis for disc disease and back pain. Among civilian populations, chronic pain is often the leading condition for which cannabis is used. Canada throughout the past year has been establishing itself as the global leader in international cannabis. As detailed in the new report,Canada has seen enormous investment gains over the past two years, with five of its top licensed producers seeing gains between 400 percent and 1,050 percent in stock prices since April 2016. Subsequently, investment activities there have remained active in advance of the adult-use program, particularly toward the end of 2017. “This report shows the immense amount of growth still to come in the Canadian medical market,” Methot concluded. “As insurance programs continue to adopt cannabis in company benefits programs, there will remain a strong need for cannabis clinics for years to come.”

Diagnosing Why Canada's Medical Market Should Thrive

May 23, 2018 08:34
ET | Source: Canada House Wellness Group Inc.
TORONTO, May  23, 2018  (GLOBE NEWSWIRE) -- Knalysis Technologies (“Knalysis”), a subsidiary of Canada House Wellness Group Inc. (CSE:CHV) (“Canada House” or the “Company”), has recently completed an exciting new project with New Frontier Data, the leader in business intelligence for the cannabis industry. New Frontier Data provides vetted, objective reporting and analysis regarding all aspects of the cannabis vertical. This past month the Company sponsored New Frontier Data’s Canada Cannabis Report: Industry Outlook 2018 which is now available for download at https://newfrontierdata.com/marketresearch/. The report, the first for the Canadian market, includes capital and performance data; detailed demand forecasts; regulatory timeline impacts; top LP size considerations; consumer preferences and other medical marketing data that can assist industry stakeholders. Knalysis currently tracks a variety of datasets from the cannabis industry in both Canada and the U.S., including product efficacy in treating symptoms and ailments and also how medical cannabis reduces and replaces the need for opiates and other pharmaceuticals. Knalysis and New Frontier Data are already looking ahead toward expanding data streams to support the global market. “This partnership is exciting for Knalysis,” says Knalysis’ President, Paul Methot. “New Frontier Data is the dominant player in the cannabis data space. We love working with the team and look forward to a long-term collaboration to bring our data to bear as Knalysis continues to track, optimize and prove the efficacy of medical marijuana.”
“We have thoroughly enjoyed working with Knalysis on our Canada Cannabis Report. The insights that their data brings to the Canadian medical market are instrumental to the work we are doing at New Frontier Data and we look forward to continuing to work with their team of innovators,” said Giadha Aguirre De Carcer, CEO and founder, New Frontier Data. About Knalysis:
Knalysis Technologies is a subsidiary of Canada House Wellness Group Inc., a publicly-traded Canadian company with one of the largest networks of cannabis clinics in Canada. We envisioned a need for health technology connecting every aspect of the medical marijuana field, and pioneered software to seamlessly link physician, provider, and patient. Purpose-built in our own clinics, Knalysis’ suite of software has been battle-tested with thousands of patients for over four years; treating a broad range of ailments and symptoms. Canada House Wellness Group Inc.
Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company’s goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit  https://www.canadahouse.ca . or  www.sedar.com
About New Frontier Data:
New Frontier Data is an independent, technology-driven analytics company specializing in the cannabis industry. It offers vetted data, actionable business intelligence and risk management solutions for investors, operators and policymakers. New Frontier Data’s reports and data have been cited in over 65 countries around the world to inform industry leaders. Founded in 2014, New Frontier Data is headquartered in Washington, D.C. with additional offices in Denver. For more information or media inquiries please visit www.newfrontierdata.com or emails us at info@newfrontierdata.com. New Frontier Data does not take a position on the merits of cannabis legalization. Rather, its mission and mandate is to inform cannabis-related policy and business decisions through rigorous, issue-neutral and comprehensive analysis of the legal cannabis industry. For more information about New Frontier Data please visit:  www.newfrontierdata.com . Cautionary Statement Regarding Forward‐Looking Information. Certain statements within this news release pertaining to the Company constitute “forward‐looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward‐looking statements”. Such “forward‐looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward‐looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company’s public disclosure record. The Company assumes no responsibility to update or revise forward‐looking information to reflect new events or circumstances unless required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. For further information, please contact:
Boom Capital Markets

Knalysis Technologies Forges Partnership with New Frontier Data

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
April 26, 2018 08:48
ET | Source: Canada House Wellness Group Inc.
TORONTO, April  26, 2018  (GLOBE NEWSWIRE) -- Knalysis Technologies (“Knalysis”), a subsidiary of Canada House Wellness Group Inc. (CSE:CHV) (“Canada House” or the “Company”) is thrilled to announce that we are one of three finalists for the KIRA Award for the Most Innovative Start-Up. The KIRAs celebrate excellence in technological, social and economic innovation across all sectors and industries in New Brunswick. “This nomination is truly an honour,” says Paul Methot, President of Knalysis Technologies, “Being recognized as an innovator in this emerging medical cannabis market really validates the importance of bringing new technologies to bear to gather critical data with the purpose of improving patient outcomes.”
The winners will be announced at the KIRA Awards on May 3rd as part of New Brunswick’s Innovation Week. About Knalysis Technologies:
Knalysis Technologies is a wholly owned subsidiary of the Canada House Wellness Group, a publicly traded Canadian company with one of the largest networks of cannabis clinics in Canada. We envisioned a need for health technology connecting every aspect of the medical marijuana field, and pioneered software to seamlessly link physician, provider, and patient. Purpose-built in our own clinics, Knalysis’ suite of software has been battle-tested with thousands of patients for over four years; treating a broad range of ailments and symptoms. Canada House Wellness Group Inc.
Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company’s goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit  https://www.canadahouse.ca . or  www.sedar.com
Cautionary Statement Regarding Forward‐Looking Information. Certain statements within this news release pertaining to the Company constitute “forward‐looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward‐looking statements”. Such “forward‐looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward‐looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company’s public disclosure record. The Company assumes no responsibility to update or revise forward‐looking information to reflect new events or circumstances unless required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. For further information, please contact:
Boom Capital Markets

Knalysis Technologies is a KIRA Award Finalist!

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
TORONTO, Feb.  02, 2018  (GLOBE NEWSWIRE) -- Knalysis Technologies “Knalysis”, a subsidiary of Canada House Wellness Group Inc. (CSE:CHV) (“Canada House” or the “Company”) would like you to get to know Knalysis better. Conferences:
For those wishing to meet our team and see our industry leading software platforms in person, our sales team will be travelling to several conferences in the coming months. On the international stage, the Knalysis team will be exhibiting at CannaTech in Tel Aviv, Israel, in March and here in North America we will be participating as an exhibitor and panelist at the World Medical Marijuana Conference in Pittsburgh in April, as we explore the different facets of technology in this industry. Focusing on conferences geared to the medical and research communities, Knalysis anticipates that these will yield critical partnerships and continue to drive our sales pipeline in key markets. Our Team is Growing:
Keeping pace with the growth of the business, the Knalysis team is expanding! We are currently adding ten new positions to our roster to focus on research and development of our platforms as well as sales and marketing. These positions will reside in the US and Canada to support operations in both markets and report to our executive team. Meet the Knalysis Executive Team:
Paul Methot, President
With over 20 years in IT, Paul has garnered experience working for some of the largest names in the industry: Microsoft, IBM, CGI, RBC, RCMP, Bank of America, and more. His career has included an award-winning platform to track and capture pedophiles, now in use by 19 countries as the CSO of IT security firm, CyberSecure, which he and his partners sold in 2004. After co-founding GreenNexxus, which measured humanity’s environmental impact, they went on to win two awards working with Cisco Systems and CBC's George Stroumboulopoulos to launch the One Million Acts of Green campaign and also working with Al Gore and his organization, The Climate Project. In recent years, Paul became CEO of Pragmatic Informatics, an IT development firm with customers across North America and Europe, and then in 2016, founded Knalysis Technologies. Today, Paul is the President of Knalysis and sits on the Board of Directors of Canada House Wellness Group. Richard Bennet, CTO
Richard holds a PhD in Computer Science from Edinburgh University. His PhD studies included the application of machine learning and data analytics. Richard co-founded a company to develop mesh networking technology for integration of legacy medical devices. Mobile Healthcare Technologies (MHN) was awarded a SMART award in the UK. Working with MHN as CTO, Richard developed and managed the application of neural networks to learn the relationship between moods and music for playlist-generation. After moving to Canada in 2009, Richard worked on a variety of ventures before founding Pragmatic Informatics. Here, Richard has overseen a variety of large software projects, from the travel aggregation space to Holographic UX (Microsoft Hololens) to blockchain and drone applications. In 2016, he co-founded Knalysis Technologies where he applies his background in machine learning and data to identify the efficacy of medical marijuana health outcomes as the CTO of Knalysis Technologies. Megan Rideout, COO
Megan’s career has always combined a passion for building deep relationships and the desire to find the right solution for a client through technology. She has had the pleasure of working with an impressive list of clients across verticals including General Motors, Deloitte, Scotiabank, Starbucks, Suncor and the Canadian Automobile Association. Megan has management experience in large scale corporate and startup environments ranging from network solutions, travel, interactive technology, and loyalty marketing. In her role as a founding member of the Expedia Corporate Travel’s (now Egencia) Canadian operation, Megan helped clients understand how to leverage Expedia’s powerful technology to create and reinforce travel policies, achieving significant savings to enhance its bottom line. Megan continued her exploration of driving behaviour with data when she stepped into the role of Director, Key Accounts at Bond Brand Loyalty (formerly Maritz Canada). Managing the P&L for Scotiabank’s B2B and credit card loyalty programs and ultimately the operation of the SCENE LP business for Bond, Megan gained a deep knowledge of customer loyalty and engagement technology to increase the value exchange between program members and the brand. Megan is now applying her expertise in client services, tech and data analysis as the COO of Knalysis Technologies, an innovator in the Canadian cannabis space. Knalysis has big plans for 2018 and beyond. Stay tuned for more exciting news. About Knalysis Technologies:
Knalysis Technologies is part of the Canada House Wellness Group, a publicly-traded Canadian company with one of the largest networks of cannabis clinics in Canada. It envisioned a need for health technology connecting every aspect of the medical marijuana field, and pioneered software to seamlessly link physicians, health providers, and patients. Purpose-built in our own clinics, Knalysis’ suite of software has been battle-tested with thousands of patients for over four years; with its data helping in treating a broad range of ailments and symptoms. Canada House Wellness Group Inc.
Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company’s goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit  https://www.canadahouse.ca . or  www.sedar.com
Cautionary Statement Regarding Forward‐Looking Information. Certain statements within this news release pertaining to the Company constitute “forward‐looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward‐looking statements”. Such “forward‐looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward‐looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company’s public disclosure record. The Company assumes no responsibility to update or revise forward‐looking information to reflect new events or circumstances unless required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Related Articles

Knalysis Technologies is On the Move

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES
TORONTO, Jan.  22, 2018  (GLOBE NEWSWIRE) -- Knalysis Technologies “Knalysis”, a subsidiary of Canada House Wellness Group Inc. (CSE:CHV) (“Canada House” or the “Company”) wishes to announce that it now has more than 12,000 medical cannabis patients on its software platforms representing 6% of the registered base in all of Canada. Its clinicians are providing the best care possible to these patients through Knalysis’ sister division, Marijuana for Trauma, and their eleven clinics across Canada. Coupled with Knalysis’ US client base, more than 32 million data points for medical cannabis treatment have been captured to date. As patient count in the Knalysis platforms continues to increase by approximately 2,500 per month, it is now seeing the impact of having big data at its fingertips. This information is critical to breaking away from anecdotal evidence of the efficacy of medical marijuana. It’s simply not good enough anymore to prescribe a treatment regimen based on what “we’ve heard” works. Patients deserve better and Knalysis platforms are ensuring that they’re getting it. Knalysis Technologies’ proprietary suite of software is helping clients grow their business through major efficiency gains and improving patient outcomes by interpreting and making good use of the significant amount of data that flows through its data platforms. Knalysis is also gaining traction with several potential new cannabis clinic clients which would add another 10,000 – 20,000 patients into its platforms by mid-year, adding 10s of millions more data points for the benefit of its analytics subscribers. All of this strengthens Knalysis’ recommendations for patient treatments and their health outcomes. This vast amount of data has led to talks with key industry reporting partners and we expect more exciting news on this front very soon. All of this progress ultimately benefits patients who have been seeking the right kind of treatment for their ailments for decades. Getting away from anecdotal evidence and proving the efficacy of medical marijuana is the key to ensuring that access to this treatment is secured for the long term. About Knalysis Technologies:
Knalysis Technologies is part of the Canada House Wellness Group, a publicly-traded Canadian company with one of the largest networks of cannabis clinics in Canada. It envisioned a need for health technology connecting every aspect of the medical marijuana field, and pioneered software to seamlessly link physician, provider, and patient. Purpose-built in our own clinics, Knalysis’ suite of software has been battle-tested with thousands of patients for over four years; treating a broad range of ailments and symptoms. Canada House Wellness Group Inc.
Canada House is the parent company of Marijuana for Trauma Inc., Knalysis Technologies and Abba Medix Corp. The Company’s goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated cannabis therapy company. For more information please visit  https://www.canadahouse.ca . or  www.sedar.com
Cautionary Statement Regarding Forward‐Looking Information. Certain statements within this news release pertaining to the Company constitute “forward‐looking statements”, within the meaning of applicable securities laws, including without limitation, statements regarding future estimates, business plans and/or objectives, sales programs, forecasts and projections, assumptions, expectations, and/or beliefs of future performance, are “forward‐looking statements”. Such “forward‐looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements. Forward‐looking statements include, but are not limited to, statements with respect to the anticipated effects of the financing, regulatory changes, timeliness of government approvals for the granting of permits and licenses, changes in medical marijuana prices, actual operating performance of facilities, competition and other risks affecting the Company in particular and the medical marijuana industry generally, including those set out in the Company’s public disclosure record. The Company assumes no responsibility to update or revise forward‐looking information to reflect new events or circumstances unless required by law. Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Related Articles

Patient Growth Equals Big Data for Knalysis Technologies and Canada House Wellness Group

New Frontier Data is an analytics company that specializes in the cannabis industry. The company offers data, business intelligence and risk management solutions for investors, operators and policymakers.

New Frontier Data

CyberSecure

These companies participate in - or service businesses that participate in - the legal cannabis industry. Our definition of cannabis includes both marijuana and hemp (and all derivatives). The collection includes both "plant-touching" and "non-plant-touching" businesses.

Cannabis

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

Digital Health

Acquired

Knalysis creates tools for better cannabis health outcomes by software that seamlessly links physicians, providers, and patients, offering a global approach to reporting, monitoring and care.

Wells Fargo Success Story

Professional Services

Platform Overview

Knalysis Technologies

Compete with Knalysis Technologies?

Compete with Knalysis Technologies?

Discover the right solution for your team